Safety and Tolerability Study of BMS-986177 in Healthy Subjects

Bristol-Myers Squibb (BMS)

Status and phase

Completed

Phase 1

Conditions

Thrombosis

Treatments

Drug: BMS-986177

Other: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

CV010-001

2015-003065-29 (EudraCT Number)

Details and patient eligibility

About

The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of BMS-986177 in healthy subjects

Enrollment

104 patients

Sex

All

Ages

18 to 55 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs and clinical laboratory determinations
Body Mass Index (BMI) of 18 to 30 kg/m2 inclusive. BMI = weight (kg)/ [height (m)]2
Females who are not of childbearing potential (i.e., who are post-menopausal or surgically sterile) and men ages 18 to 55, inclusive

Exclusion Criteria:

Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations beyond what is consistent with the target population
Any condition that could affect drug absorption
Other protocol-defined exclusion criteria could apply